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MicroRNAs (miRNAs) are small non-coding RNAs that regulate expression of various
target genes. miRNAs are expressed in a tissue-specific manner and play important
roles in cell proliferation, apoptosis, and differentiation. Epigenetic alterations such as
DNA methylation and histone modification are essential for chromatin remodeling and
regulation of gene expression including miRNAs. The CCCTC-binding factor, CTCF, is
known to bind insulators and exhibits an enhancer-blocking and barrier function, and more
recently, it also contributes to the three-dimensional organization of the genome. CTCF
can also serve as a barrier against the spread of DNA methylation and histone repressive
marks over promoter regions of tumor suppressor genes. Recent studies have shown
that CTCF is also involved in the regulation of miRNAs such as miR-125b1, miR-375, and
the miR-290 cluster in cancer cells and stem cells. miR-125b1 is a candidate of tumor
suppressor and is silenced in breast cancer cells. On the other hand, miR-375 may have
oncogenic function and is overexpressed in breast cancer cells. CTCF is involved in the
regulation of both miR-125b1 and miR-375, indicating that there are various patterns
of CTCF-associated epigenetic regulation of miRNAs. CTCF may also play a key role in
the pluripotency of cells through the regulation of miR-290 cluster. These observations
suggest that CTCF-mediated regulation of miRNAs could be a novel approach for cancer
therapy and regenerative medicine.
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INTRODUCTION
MicroRNAs (miRNAs) are small non-coding RNAs that regulate
various target genes and play important roles in cell prolif-
eration, apoptosis, and differentiation. One of the important
mechanisms of miRNA expression is epigenetic alteration such
as DNA methylation and histone modification. The CCCTC-
binding factor, CTCF, is known to bind insulators and exhibits
an enhancer-blocking and barrier function, and more recently,
it also contributes to the three-dimensional organization of the
genome. Although, there are a number of studies describing reg-
ulation of miRNA expression including epigenetic alterations,
only a few studies have reported the association between miRNA
expression and CTCF. In this report, we review recent studies
regarding miRNAs and CTCF, and discuss about roles of CTCF
in the regulation of miRNA expression.
miRNA
miRNAs are ∼22 nucleotide (nt) non-coding RNAs that can
post-transcriptionally downregulate the expression of various tar-
get genes. Currently,∼1500 human miRNAs have been identified
in the human genome, and each miRNApotentially controls hun-
dreds of target genes. In animals, miRNA genes are generally tran-
scribed by RNApolymerase II (pol II) to form primary transcripts
(pri-miRNAs). Pol II transcribed pri-miRNAs are capped with
Abbreviations: miRNA, microRNA; RISC, RNA-induced silencing complex; ERα,
estrogen receptor α; ESC, embryonic stem cell; EEmiRC, early embryonic miRNA
cluster; IE, intragenic enhancer.
7-methylguanosine and are polyadenylated. The nuclear RNase
III enzyme Drosha and its co-factor DGCR8 process pri-miRNAs
into ∼60 nt precursor miRNAs (pre-miRNAs), which form an
imperfect stem-loop structure. Pre-miRNAs are transported into
the cytoplasm by exportin 5 and are subsequently cleaved by
Dicer into mature miRNAs which are then loaded into the RNA-
induced silencing complex (RISC). The miRNA/RISC complex
downregulates specific gene products by translational repres-
sion via binding to partially complementary sequences in the 3′
untranslated regions of the target mRNAs or by directing mRNA
degradation via binding to perfectly complementary sequences.
miRNAs are expressed in a tissue-specific manner and play
important roles in metabolism, proliferation, apoptosis, and dif-
ferentiation. Moreover, recent studies have shown a link between
aberrant expression of miRNAs and the development of cancer
(Calin and Croce, 2007; Cho, 2007; Saito et al., 2009).
EPIGENETIC REGULATION OF miRNA EXPRESSION
Since miRNAs can have large-scale effects through regulation of a
variety of genes duringmammalian development and carcinogen-
esis, an understanding of the regulatory mechanisms controlling
miRNA expression is important. There are several reports of
transcription factors binding to the promoter regions of specific
miRNA genes and activating the transcription of pri-miRNAs,
resulting in increased expression of mature miRNAs. c-Myc binds
to the regulatory region of the miR-17-92 cluster and increased
expression of c-Myc leads to the activation of the miRNAs in the
cluster (O’Donnell et al., 2005).
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Epigenetic alterations such as DNA methylation and histone
modification play critical roles in chromatin remodeling and reg-
ulation of gene expression in mammalian development and in
human diseases. Many miRNAs are expressed in a tissue- and
tumor-specific manner, implying that some miRNAs are sub-
ject to epigenetic control. We have shown that miR-127, which is
embedded in a CpG island, is strongly induced by treatment with
DNA methylation inhibitors and histone deacetylase inhibitors,
indicating that some miRNA genes are controlled by epigenetic
alterations in their promoter regions and can be activated by
chromatin modifying drugs (Saito et al., 2006, 2009). Lujambio
et al. (2007) compared miRNA expression profiling between
the wild-type HCT116 colon cancer cell line and HCT116 after
genetic disruption of both DNA methyltransferase (DNMT) 1 and
DNMT3b (DKO cells). They found that 18 out of 320 miRNAs
are significantly upregulated in DKO cells. In particular, miR-
124a is silenced by its own CpG island hypermethylation in
human tumors, but can be activated by inhibition of DNAmethy-
lation. They also demonstrated that the oncogene CDK6 is a
target of miR-124a and that epigenetic silencing of miR-124a in
cancer cells modulates CDK6 activity. It has been reported that
miR-9-1 and miR-9-3 are potential tumor suppressor miRNAs
and are inactivated by epigenetic mechanisms in human can-
cers (Lehmann et al., 2008; Lujambio et al., 2008). miR-34a was
identified as a target of p53 and induces a G(1) cell cycle arrest,
senescence and apoptosis (He et al., 2007; Tazawa et al., 2007).
miR-34a expression is silenced in several types of cancer includ-
ing pancreatic cancer due to aberrant CpG methylation of its
promoter. Re-expression of miR-34a in a pancreatic carcinoma
cell line induced senescence and cell cycle arrest at least in part
by targeting CDK6, indicating that miR-34a represents a tumor
suppressor gene which is inactivated by CpGmethylation in pan-
creatic cancer (Lodygin et al., 2008). miR-34b and miR-34c are
also reported to be silenced by aberrant CpG island methyla-
tion in colorectal cancer (Toyota et al., 2008). Thus, a number
of miRNAs are under epigenetic control and disruption of DNA
methylation patterns and histone modification in the promoter
regions of miRNAs might be associated with cancer development
(Esteller, 2011).
The CCCTC-binding factor, CTCF, is known to bind insu-
lators and exhibits an enhancer-blocking function. CTCF can
also serve as a barrier against the spread of DNA methylation
and histone repressive marks over promoter regions of tumor
suppressor genes (Recillas-Targa et al., 2011). CTCF is a highly
conserved multifunctional zinc finger protein involved in tran-
scriptional repression and activation, insulation, epigenetic events
such as imprinting of the H19/IGF2 locus, and X-inactivation,
and which binds preferentially to unmethylated DNA (Filippova,
2008; Phillips and Corces, 2009). Moreover, CTCF play impor-
tant roles during carcinogenesis: epigenetic silencing of tumor
suppressor genes such as p16 and Rb (De La Rosa-Velazquez
et al., 2007; Witcher and Emerson, 2009), apoptosis of breast
cancer cells (Docquier et al., 2005), and regulation of impor-
tant tumor suppressor genes such as p53 (Recillas-Targa et al.,
2011; Saldana-Meyer and Recillas-Targa, 2011). These findings
suggest that CTCF may be involved in epigenetic regulation of
non-coding RNAs including miRNAs as well as coding RNAs.
DISRUPTION OF CTCF BINDING AT THE miR-125b1 CPG
ISLAND IN HUMAN CANCERS
Recent studies have reported that expression of miR-125b is
downregulated in various human cancers including glioblastoma,
prostate cancer, ovarian cancer, and breast cancer (Scott et al.,
2007; Zhang et al., 2011). In addition, miR-125b suppresses onco-
genes such as EST1, ERBB2, ERBB3, and Bak1 as its targets,
suggesting that miR-125b functions as a tumor suppressor. DNA
hypermethylation at the CpG island of miR-125b was observed in
cell lines and in tissue samples from patients with breast cancer
(Zhang et al., 2011).
Soto-Reyes et al. (2012) investigated epigenetic alterations
such as DNA methylation and histone modification, and asso-
ciation of CTCF at the locus of miR-125b1 in breast cancer
cells. They found aberrant DNA methylation of the miR-125b1
CpG island and that disruption of CTCF binding correlated
with incorporation of repressive histone modifications such as
histone H3 lysine 9 (K9) trimethylation and histone H3 K27
trimethylation in cancer cells. In normal breast cells expressing
miR-125b1, CTCF might prevent the recruitment of epigenetic
silencing components, such as DNA methylation and repres-
sive histone modifications, and also favors an open chromatin
structure. In breast cancer cells, the loss of CTCF is associated
with CpG island methylation and the gain of repressive his-
tone modifications such as histone H3 K9 trimethylation and
histone H3 K27 trimethylation. Disruption of CTCF binding at
CpG island induces silencing of miR-125b1 expression (Figure 1).
These findings suggest that CTCF plays an important role in the
regulation of the tumor suppressor miR-125b1 in cooperation
with DNAmethylation and histone modification in breast cancer
cells. A recent study has also demonstrated that miR-125b1 can
be silenced by DNA methylation, which may lead to activation of
the ETS1 proto-oncogene and a worse prognosis in breast cancer
FIGURE 1 | Disruption of CTCF binding at the miR-125b1 CpG island in
human cancers. In normal breast cells, CTCF might prevent the
recruitment of epigenetic silencing components, such as DNA methylation
and repressive histone modifications, and also favors an open chromatin
structure. Meanwhile, in breast cancer cells, the loss of CTCF is associated
with CpG island methylation and the gain of repressive histone
modifications such as histone H3 K9 trimethylation and histone H3 K27
trimethylation. Open circle, unmethylated DNA; filled circle, methylated
DNA; H3K9Me, histone H3 K9 methylation; H3K27Me, histone H3 K27
methylation.
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patients (Zhang et al., 2011). Reactivation of the tumor sup-
pressor miR-125b1 by epigenetic therapy using DNAmethylation
inhibitors may have clinical promise for the treatment of breast
cancer patients.
ROLE OF CTCF IN THE REGULATION OF miR-375 EXPRESSION
IN BREAST CANCER CELLS
Breast cancer is the leading cause of cancer death in women
worldwide. Estrogen receptor α (ER α) upregulation causes
abnormal cell proliferation in approximately 70% of breast can-
cers (Shoker et al., 1999; Vargo-Gogola and Rosen, 2007). A
recent study has reported that miR-375 is overexpressed in ERα-
positive breast cancer cell lines and plays an important role
in cell proliferation (de Souza Rocha Simonini et al., 2010).
There are CpG islands in the upstream region of the miR-375
gene. DNA hypermethylation is observed in the CpG island
of ERα-positive breast cancer cells showing high expression of
miR-375, whereas DNA hypomethylation and histone H3 K9
dimethylation are observed in the CpG islands of ERα-negative
breast cancer cells. CTCF binds to unmethylated DNA in the
CpG islands of ERα-negative cells and induces silencing of
miR-375 expression. These findings suggest that overexpression
of miR-375 is caused by dissociation of CTCF from the CpG
island of miR-375 gene via loss of epigenetic marks including
local DNA hypomethylation and histone H3 K9 dimethylation
(de Souza Rocha Simonini et al., 2010) (Figure 2). It has been
shown that miR-375 suppresses Ras dexamethasone-induced 1
(RASD1) as its potential target, and RASD1 can suppress the
growth of breast cancer cells and down-regulate ERα expres-
sion (Vaidyanathan et al., 2004; de Souza Rocha Simonini et al.,
2010). Thus the modulation of ERα expression by miR-375
is achieved through the repression of RASD1. These observa-
tions provide a possibility that inhibition of miR-375 could be a
novel clinical approach for the treatment of ERα-positive breast
cancer.
FIGURE 2 | Role of CTCF in the regulation of miR-375 expression in
breast cancer cells. In ERα-positive breast cancer cells, DNA
hypermethylation is observed in the CpG island of the miR-375 gene, and
miR-375 expression is activated. On the other hand, in ERα-negative breast
cancer cells, DNA hypomethylation and histone H3 K9 dimethylation are
observed, resulting in silencing of miR-375 expression by binding of CTCF
in the CpG island. Open circle, unmethylated DNA; filled circle, methylated
DNA; H3K9Me, histone H3 K9 methylation.
CTCF MODULATES EXPRESSION OF THE EARLY
EMBRYONIC miRNA CLUSTER
Human embryonic stem cells (ESCs) are derived from the
inner cell mass of the human blastocyte and can be kept in
an undifferentiated, self-renewing state indefinitely. ESCs have
the advantage of being pluripotent, which endows them with
the ability to differentiate into virtually every cell type in the
human body. Thus, ESCs have gained popularity as a poten-
tially ideal cell candidate for regenerative medicine. The early
embryonic miRNA cluster (EEmiRC) has been identified in
ESCs of mammals, and shows a remarkable cross-eutherian
species conservation at the levels of both pre-miRNA hair-
pins and the core-promoter region (Houbaviy et al., 2003,
2005). EEmiRC encodes 7 miRNAs (miR-290, -291a, -292,
-291b, -293, -294 and -295), which have been labeled as ESC-
specific/pluripotency-associated miRNAs controlling cell-cycle
progression, proliferation, and DNA methylation in undifferen-
tiated/pluripotent cells. Therefore, understanding the biology of
ESCs requires detailed knowledge of the mechanisms regulating
EEmRC expression.
Little is known about the molecular mechanisms underly-
ing the regulation of the EEmiRC expression. Recent studies
have showed that the sequences upstream to the EEmiRC pro-
moter contains active binding sites for Nanog, Oct3/4, Sox2,
Tcf3, c-Myc, and 4n-Myc. Histone H3 K4 trimethylation and
histone H3 K27 trimethylation were observed in ESCs and in
differentiated cells, respectively (Chen et al., 2008; Judson et al.,
2009). However, attempts to activate EEmiRC expression by
ectopic expression of these individual transcriptional factors in
fibroblasts were unsuccessful, suggesting that EEmiRC expres-
sion is under epigenetic control (Judson et al., 2009). Tata
et al. (2011) identified a 332-bp intragenic enhancer (IE) region
within the EEmiRC, which is able to modulate the transcription
of the mouse EEmiRC locus. These miRNAs involve pluripo-
tency factors and epigenetic mechanisms in pluripotent and
differentiated cells. The results of chromatin immunoprecipita-
tion (ChIP) assays demonstrated that the level of occupancy of
Oct3/4, Sox2, and CTCF in this region gradually and dramat-
ically decreased during ESC differentiation, suggesting a func-
tional role for these transcription factors in regulating EEmiRC
expression. This IE also contains a CpG island showing a dif-
ferential pattern of DNA and histone methylation marks during
differentiation of ESCs. Since, miR-290 cluster miRNAs have
been shown to suppress Rbl2 as their target and Rbl2 mod-
ulates DNMTs (Benetti et al., 2008; Sinkkonen et al., 2008),
EEmiRC may comprise a feedback loop with DNMTs. These
findings indicate that this region plays a critical role in the
regulation of EEmiRC expression, presumably through binding
of transcription modulators such as Oct3/4, Sox2, and CTCF.
Cohesin is a DNA-binding protein complex that is essential for
sister chromatid cohesion and facilitates the repair of damaged
DNA. Recent experiments have revealed that cohesin binds to
the same sites in mammalian genomes as CTCF and cooperates
with CTCF in regulating gene expression (Herold et al., 2012).
Epigenetic effectors including CTCF and cohesin may modu-
late the pluripotency of cells through the regulation of miR-290
cluster.
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Table 1 | miRNAs associated with CTCF.
miRNA Expression Target genes Association with CTCF References
miR-125b1 Decreased in human cancers
including glioblastoma, prostate
cancer, ovarian cancer and breast
cancer
EST1, ERBB2, ERBB3,
Bak1
In breast cancer cells, disruption
of CTCF binding at the miR-125b1
CpG island correlated with DNA
methylation and methylation of
histone H3K9 and K27 induces
silencing of miR-125b1 expression
Scott et al., 2007; Zhang
et al., 2011; Soto-Reyes
et al., 2012
miR-375 Overexpressed in ERα-positive
breast cancer cells
RASD1 In ERα-positive breast cancer
cells, miR-375 overexpression
was caused by dissociation of
CTCF from the miR-375 promoter
via loss of epigenetic marks
including local DNA
hypomethylation and histone H3
K9 methylation
de Souza Rocha Simonini
et al., 2010
miR-290 cluster miR-290 cluster (miR-290, -291a,
-292, -291b, -293, -294 and -295)
have been identified as ESC-
specific/pluripotency-associated
miRNAs
Rbl2 CTCF binds to intragenic
enhancer region within the early
embryonic miRNA cluster
(EEmiRC) and modulates the
expression of the EEmiRC
Houbaviy et al., 2003,
2005; Benetti et al.,
2008; Chen et al., 2008;
Sinkkonen et al., 2008;
Judson et al., 2009; Tata
et al., 2011
PERSPECTIVES AND CONCLUSION
Table 1 shows a summary of the association between miRNAs
and CTCF. These findings indicate that the insulator protein
CTCF plays various roles in the regulation of miRNAs such as
miR-125b1, miR-375, and themiR-290 cluster during mammalian
development and carcinogenesis. miR-125b1 is a candidate of
tumor suppressor and is silenced in breast cancer cells. On the
other hand,miR-375 may have oncogenic function and is overex-
pressed in breast cancer cells. CTCF is involved in the regulation
of both miR-125b1 and miR-375, indicating that there are various
patterns of CTCF-associated epigenetic regulation of miRNAs.
CTCF-mediated regulation of these miRNAs may provide a novel
therapeutic approach for breast cancer. CTCF may also play a
key role in the pluripotency of cells through the regulation of
miR-290 cluster. Since, the link between miRNAs and CTCF has
only just begun to be understood, other miRNA genes regu-
lated by CTCF will be identified. Further studies are necessary
to investigate whether CTCF-mediated regulation of miRNAs
could be a novel approach for cancer therapy and regenerative
medicine.
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